CBX1 and nasopharyngeal carcinoma: We first assessed CBX1 mRNA expression in the active and evaded immune subtypes of NPC, which were classified in our previous study.[24] In the 14 NPC patients who received anti‐PD‐1 therapy plus chemotherapy in our EGAS00001004542 dataset,[24] we found a significantly higher level of CBX1 expression in the evaded immune subtype than in the active immune subtype (Figure 7A).